Navigation Links
Hurel Corporation Launches Cell-Based In Vitro Testing Product Suite, Milestone in Movement Away from Use of Live Animals in Drug and Toxicity Testing
Date:7/16/2013

NORTH BRUNSWICK, N.J., July 16, 2013 /PRNewswire/ -- Hurel Corporation ("Hurel"), a world-leading provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms, today announced the commercial launch of its innovative in vitro product suite utilizing liver cells of the rat, dog and human species.  The announcement coincided with Hurel's Scientific Advisory Board Chairman Dr. Leslie Z. Benet's presentation of data generated using Hurel's products, which he gave at The Boston Society's HT-ADME 2013 conference, held today at the Broad Institute in Cambridge, Massachusetts.  The commercial availability of the Hurel products marks a milestone in the transition away from the use of live animals in drug and toxicity testing, towards new cell-based technologies that can substitute for and deliver more usefully predictive results than animal-based testing often can.

Hurel's cell-based products, respectively named HμRELHuman™, HμRELDog™, and HμRELRat™, are made from actual liver cells derived from the human, dog, or rat species.  The cells, which have previously been cryopreserved, are reconstituted and restored to functionality in Hurel's laboratories.  Formulated as a "co-culture" of two different, naturally occurring types of cells found in the liver, Hurel's products are distinctive for their high metabolic competency and responsiveness, the stability of their response levels day after day, and their long-lived endurance.  These attributes together enable researchers to perform kinds of experiments that may require a week or multiple weeks to carry out, cannot be completed in the limited span of days or hours afforded by the in vitro products in wide use today, and thus have frequently been conducted in live animals up until now. 

Dr. Benet's presentation at HT-ADME 2013 demonstrated, within the specific scientific arena of Drug Metabolism and Pharmacokinetics, that Hurel's products can provide greatly improved insight into drugs that take a long time to be biochemically broken down (metabolized) by the liver and thus "cleared" from the bodily system; can identify differences in the metabolite molecules that a drug produces when administered in humans, dogs, or rats, respectively; and can provide in vitro data that justifies the early elimination of inappropriate pre-clinical animal species from further use in the investigation of a particular pre-clinical drug candidate.   In sum, Dr. Benet's presentation demonstrated that Hurel's products represent an important step in the pathway of reducing animal tests and substituting them with in vitro cell-based tests.

"Recently, the nation's attention was riveted by the news that the National Institutes of Health is retiring its chimpanzees from further use in biomedical research.  Hurel is pleased to demonstrate that its cell-based products comprise powerful, broadly applicable new tools that in many applications are not only more effective and predictive than existing in vitro methods, but are also more effective and predictive than live animal testing, and thus afford the technological means to extend the NIH's reduction in the use of lab animals to include increasing numbers of animals of other species in addition to chimps," said Robert Freedman, Hµrel's Chairman and CEO.  "Hurel's launch of the HμRELHuman™, HμRELDog™, and HμRELRat™ product line helps respond to the needs of society, the regulatory agencies and industry to reduce the extent of animal testing in drug development."

About Hurel
Hurel Corporation, based in North Brunswick, NJ and Beverly Hills, CA, is a world-leading provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms that are used by major pharmaceutical research organizations in pre-clinical drug development, as well as in the toxicological testing of industrial materials and consumer products.  Hurel recently consummated a $9.2 million Series A preferred stock financing facility led by Spring Mountain Capital, in which the Humane Society of the United States is also a participant.  In addition to its currently offered line of HμRELHuman™, HμRELDog™, and HμRELRat™ products, the company is also developing HμRELFlow™, which augments the power of its cell-based technologies through the addition of microfluidics.  More information about Hurel can be found at http://hurelcorp.com/.


'/>"/>
SOURCE Hurel Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
2. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
3. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
4. Neogen Corporation Announces 2nd Quarter Results Conference Call
5. Luminex Corporation to Present at JP Morgan Healthcare Conference
6. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
7. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
8. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
9. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
10. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
11. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... The publishing industry has ... publishing is one of the popular publication models that has received wider acknowledgement ... and 3000+ International Conferences across the globe, OMICS International is all ...
(Date:2/9/2016)... 2016 This market research report on the ... prospects of the market in terms of revenue (USD ... in the manufacture of microbiology culture media and related ... market snapshot providing the overall information of various market ... section also provides the overall information and data analysis ...
(Date:2/9/2016)... BOSTON , Feb. 9, 2016 ... a data-driven, biological research approach, has announced the ... Financial Officer and Chief Operating Officer. Haddock brings ... corporate finance, including 12 years in senior financial ... global experience in business organizational management. ...
(Date:2/8/2016)... Feb. 8, 2016 Should antibiotic bone cement ... products to prevent infection after standard total hip or ... at ECRI Institute have been fielding a lot lately. ... Your Bottom Line?" --> "Antibiotic ... --> While there isn,t a ...
Breaking Biology Technology:
(Date:2/1/2016)...  Today, the first day of American Heart Month, ... a first of its kind workplace health solution that ... the first application of Watson ... and Welltok will create a new offering that combines ... delivered on Welltok,s health optimization platform. The effort is ...
(Date:1/27/2016)... CHESTER, Ohio , Jan. 27, 2016  Rite ... supplier based in West Chester, Ohio ... their award winning service staff, based in ... technical capacity and ability to provide modifications, installations and ... John Dovalina , CEO of PLUS, commented, "PLUS has ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ... Market 2016-2020"  report to their offering. ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the addition ...
Breaking Biology News(10 mins):